Cytokinetics CEO Robert Blum: An Interview With “The Pink Sheet” DAILY (Part 2 Of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
In the second part of the interview at the BIO Investor forum, CEO Robert Blum discusses Cytokinetics’ deal with Amgen and long-range commercialization goals.
You may also be interested in...
Cytokinetics CEO Robert Blum: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Chief exec sits down with “The Pink Sheet” DAILY at BIO Investor Forum to discuss lead candidates in oncology and heart failure, and partnering with big pharma.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.